Latest Regulatory Approval News

Boab Metals has taken a major step forward in developing its Sorby Hills Lead-Silver-Zinc Project by acquiring the DeGrussa Processing Plant and completing a $6 million capital raise, positioning the company for a Final Investment Decision later this year.

Critical Minerals Group (CMG) has made significant strides in its vanadium battery energy storage solutions and upstream mine development, supported by a $2.7 million entitlement offer. The company is targeting delivery of vanadium flow battery projects by 2026 amid growing demand for long-duration energy storage in Australia.

EVE Health Group has completed its acquisition of Nextract, raised $1 million to fund manufacturing, and achieved key regulatory and commercial milestones for its pharmaceutical products targeting erectile dysfunction and dysmenorrhea.

iTech Minerals has significantly extended the strike length of gold-antimony mineralisation at its Reynolds Range Project, revealing new high-priority drill targets and advancing its lithium deal with SQM.

CZR Resources has secured shareholder and regulatory approval to sell its Robe Mesa iron ore project for A$75 million, positioning the company to focus on promising gold and base metal exploration in Western Australia.

Acrux Limited has secured a decade-long licensing agreement with Servacure to commercialise its FDA-approved Dapsone 5% Gel in Saudi Arabia, marking a strategic step in its global expansion.

Titanium Sands Limited has secured retention licenses for four critical exploration areas and is progressing its Environmental Impact Assessment in Sri Lanka, while engaging government officials and local landowners to navigate regulatory hurdles.

Silver Mines Limited progresses regulatory approvals for its flagship Bowdens Silver Project in NSW while acquiring promising US assets, enhancing its exploration pipeline with minimal upfront costs.

INOVIQ Limited reports breakthrough results for its ovarian cancer screening test achieving perfect early-stage detection, alongside promising advances in its CAR-exosome cancer therapy program.

Nyrada reports successful completion of five cohorts in its Phase I trial of Xolatryp with no safety concerns, alongside compelling preclinical neuro- and cardioprotective data. A Phase IIa trial targeting heart attack patients is slated for early 2026.

Next Science reports a 10% decline in quarterly product sales but advances a $50 million asset sale to Demetra Holdings, signaling a pivotal shift in its business strategy.

Jupiter Mines reports record FY2025 manganese sales and production at Tshipi mine, while Q4 earnings dip due to lower prices and higher costs. Exxaro’s planned majority acquisition signals a new chapter for the asset.